Suspension of trading

Analyst Reco. CureVac

Stocks

Delayed Nasdaq Other stock markets 08:00:00 06/01/26 am AEDT			5-day change	1st Jan Change
4.660 ^USD	-0.21%		-.--%	+3.10%

15/04	Evotec Taps CureVac Executive as COO	MT
06/01	CureVac ends coverage after BioNTech acquisition

06/01	CureVac ends coverage after BioNTech acquisition
26/11	CureVac acquisition advances as cash runway secured to 2028
18/08/25	CureVac: Despite weak Q2, acquisition remains on track
14/07/25	CureVac: Pipeline pruning’s nasty effect
26/06/25	UBS Downgrades CureVac to Neutral From Buy, Adjusts Price Target to $5.50 From $12	MT
13/06/25	Jefferies Downgrades CureVac to Hold From Buy, $5 Price Target	MT
13/06/25	CUREVAC : Downgraded to Neutral by Jefferies	ZD
02/06/25	CureVac: Successful cash burn reduction
30/04/25	UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating	MT
11/04/25	CureVac: 2025 will be less costly
21/02/25	CureVac: The mid-term effect of pipeline pruning
12/12/24	CureVac: Licensing deal boosts bank account
09/12/24	CureVac: Positive one-off overshadows pipeline dryness
02/09/24	CUREVAC : Deutsche Bank reiterates its Neutral rating	ZD
01/09/24	CureVac: A beneficial deal
20/08/24	CureVac: Much noise at CureVac, overshadowing recent positive pipeline progress
24/05/24	CureVac: Significant cash drain in the Q1
03/05/24	CureVac: A missed opportunity
27/04/24	UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	MT
25/04/24	Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	MT
23/12/23	Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10	MT
29/11/23	CUREVAC : An untrimmed pipeline becomes costly
28/11/23	CUREVAC : Unchanged cash drain
21/08/23	CUREVAC : A missed opportunity
26/07/23	CUREVAC : Higher losses expected in future